Fibrocalculous Pancreatic Diabetes: Changing Clinical Spectrum and Glycaemic Response to Pioglitazone Authors: Don David, Manjunath Goroshi, Vanishri Ganakumar, Vikrant Ghatnatti Published: 2026 ABSTRACT Introduction:Fibrocalculous pancreatic diabetes (FCPD) is a unique form of diabetes characterised by irreversible damage to the pancreatic parenchyma with intraductal calcification, progressively leading to beta-cell damage. The classical clinical presentation of FCPD is evolving, with a declining frequency of typical phenotypes and increasing involvement of individuals with normal BMI and older age at presentation. This Study evaluated the clinical and demographic profile of patients with FCPD in North Karnataka and compared the glycaemic response to pioglitazone.Methods:This was a single-centre retrospective observational study done at a tertiary care endocrinology centre. Patients with FCPD diagnosed between December 2019 and December 2024 were retrospectively analysed. Clinical characteristics, imaging and glycaemic data were collected. Patients with suboptimal glycaemic control despite insulin therapy (HbA1c >9%) were initiated on add-on pioglitazone or metformin, and within-group changes in HbA1c and daily insulin requirement over 3 months were evaluated using paired t-tests.Results:The mean age at diagnosis was 42 ± 11.97 years, with a mean diagnostic delay of 2.83 ± 1.8 years. Only 10.5% of patients were correctly diagnosed with FCPD at initial presentation. Despite receiving insulin therapy, 76.5% of patients experienced progressive weight loss, and 76.8% reported frequent hypoglycaemic episodes.Conclusion:FCPD in North Karnataka demonstrated atypical clinical features (low BMI and chronic diarrhoea) with delayed diagnosis and frequent hypoglycaemia. Glycaemic control could be optimised with short-acting insulin. Pioglitazone compared with metformin significantly improved glycaemic parameters and reduced insulin requirement, due to its effect on hepatic insulin resistance. INTRODUCTION Fibrocalculous pancreatic diabetes (FCPD) is an uncommon form of diabetes occurring predominantly in developing countries.[1] It is characterised by irreversible damage to the pancreatic parenchyma with intraductal calcification, progressively leading to beta-cell damage and diabetes. FCPD was an important cause of diabetes in the young; recent studies by Unnikrishnan et al. and Dasgupta et al.[123] suggest a declining trend in the classical presentation of FCPD due to improved nutrition, changing epidemiology, and better diagnostic modalities. The disease is increasingly affecting people with a normal BMI as well as subjects in an older age group.[3] Distinguishing FCPD from other forms of diabetes is critical owing to its brittle glycaemic course, differing treatment strategies, and specific risk management challenges.[123] The factors attributed to the etiopathogenesis of FCPD are malnutrition, cassava intake, micronutrient deficiencies, and serine protease inhibitor kazal type 1 (SPINK-1) gene variations.[45] Management of FCPD requires a comprehensive approach that includes nutritional optimisation, pain management, and correction of exocrine and endocrine pancreatic insufficiency.[236] But some studies, like Singla et al.[78] evaluated the degree of insulin resistance in FCPD and showed a similar degree of insulin resistance as compared to T2DM. However, the literature evaluating the role of insulin-sensitising drugs, such as metformin and pioglitazone, in FCPD remains limited. This study aimed to evaluate the demographic and clinical profile of patients with FCPD, including total insulin requirements and patterns of insulin use and to assess the glycaemic effects of pioglitazone and metformin in a subset of patients. MATERIALS AND METHODS This study was a retrospective analysis of patients diagnosed with FCPD who attended the outpatient Endocrinology department between December 2019 and December 2024. All included patients had a minimum follow-up duration of three years. All patients aged more than 18 years who fulfilled the diagnostic criteria for FCPD were included. FCPD was diagnosed[123] based on previously described criteria. The diagnosis required the presence of diabetes mellitus, defined according to the American Diabetes Association criteria.[910] In addition, imaging evidence of pancreatic structural abnormalities was required, including pancreatic parenchymal atrophy with intraductal calculi with or without parenchymal calcification detected on non-contrast computed tomography of the abdomen or ultrasonography. Furthermore, other known causes of chronic pancreatitis were excluded, including a history of chronic alcohol consumption, biliary tract stones, hypertriglyceridemia, hypercalcaemia, and congenital or structural abnormalities of the pancreas. Patients with less than 3 years of follow-up or those lost to follow-up were excluded from the study. All the details regarding demographic characteristics, the initial diagnosis and the lag period between the onset of diabetes and the diagnosis of FCPD were noted. Glycaemic parameters, including fasting blood glucose, postprandial blood glucose, and glycated haemoglobin (HbA1c), were recorded at the time of presentation. Treatment details, hypoglycaemic episodes, insulin dose requirements and type of insulin were noted. Patients with suboptimal glycaemic control despite insulin therapy (HbA1c >9%) were started on metformin (1500 mg) or pioglitazone (15-30 mg). Insulin requirements and HbA1c levels were compared at baseline and after three months of metformin or pioglitazone therapy. Microvascular complications were assessed systematically. Diabetic neuropathy was defined as vibration perception threshold (VPT) more than >15 volts assessed by using a biothesiometer (Dhansai Lab, Mumbai, India) at seven different sites in both feet.[11] Diabetic nephropathy was defined as a spot urinary albumin/creatinine ratio of more than 30 mg/gm creatinine on two different occasions and/or eGFR <60 mL/min/1.73 m², even in the absence of albuminuria.[1213] Diabetic retinopathy was evaluated using non-mydriatic fundus photography (3Nethra Classic, Forus Health, Bengaluru, India) and classified according to the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria into non-proliferative and proliferative retinopathy.[11] Statistical analysis was done using IBM SPSS version 24. The description of quantitative (numerical) variables was stated in the form of mean ± standard deviation. Treatment responses to pioglitazone and metformin were evaluated using paired t-tests, with statistical significance defined as a P value < 0.05. Ethical aspects Ethical Clearance for the study was obtained from the JNMC Institutional Ethics Committee, Nehru Medical College, Belagavi. The approval letter is MDC/JNMCIEC/201, and the date of issue is 21/07/2025. Written and informed consent was waived for participation in the study and use of patient data for research and educational purposes. Procedures followed the guidelines laid down in the Declaration of Helsinki(1964) and as revised later. RESULTS A total of 200 patients with a diagnosis of FCPD were identified; 38 were excluded owing to inadequate follow-up. One hundred and sixty-two patients were included in the analysis, with a mean age of presentation of 42 ± 11.97 years, and 132/162 (81.45%) were men [Table 1]. Out of 162 patients, 89 patients (54.9%) were initially misdiagnosed as Type 1 diabetes or latent Autoimmune Diabetes in Adults (LADA), 56 (34.5%) were misdiagnosed as Type 2 Diabetes, and only 17 (10.5%) patients were correctly diagnosed to have FCPD at the time of presentation. Mean delay in diagnosis of FCPD from the onset of Diabetes was 2.83 ± 1.8 years. Mean BMI of our patient cohort was 19.13 ± 3.12 kg/m2. Only 35 patients (21.6%) reported chronic diarrhoea lasting more than four weeks. At presentation, the mean glycaemic parameters were as follows: fasting blood glucose 226 ± 96.11 mg/dL, postprandial blood glucose 368.9 ± 135.8 mg/dL, and glycated haemoglobin (HbA1c) 11.01 ± 2.73% [Table 1]. All patients had intraductal calculi with severe atrophy of pancreatic parenchyma on imaging (Computerised tomography was performed in 28 patients, and Ultrasonography in 134 patients). Only 58 patients (35.8%) showed parenchymal calcification. Table 1Baseline characteristics of FCPD patientsVariableMean±SDAge at presentation42±11.97 yearsDelay in diagnosis of FCPD2.83±1.8 yearsBMI19.13±3.12 kg/m²Glycemic profile at presentation Fasting blood sugar (FBS):226±96.11 mg/dl Postprandial blood sugar (PPBS):368.9±135.8 mg/dl HbA1c:11.01±2.73%BMI, body mass index; HbA1C, glycated Hb; SD, standard deviation Baseline characteristics of FCPD patients BMI, body mass index; HbA1C, glycated Hb; SD, standard deviation At presentation, 182 patients (77.1%) were receiving insulin therapy either alone or in combination with oral hypoglycaemic agents, while 37 patients were treated exclusively with oral hypoglycaemic drugs. Among those on insulin, 96 of 125 patients (76.8%) reported frequent episodes of severe hypoglycaemia, predominantly occurring during the pre-prandial period and during the night. With respect to insulin regimens, 82 patients (65.6%) were using premixed insulin formulations containing 30% regular insulin and 70% NPH insulin, whereas the remaining patients were managed with a basal–bolus regimen. The total requirement of insulin at the time of presentation was 0.8 units/kg/day. One hundred and twenty-four patients (76.5%) presented with progressive weight loss despite adequate treatment of diabetes. All patients were started on insulin after the diagnosis of FCPD. Seventy-eight patients (48.1%) were on premix insulin 50% regular insulin and 50% NPH insulin twice daily, 65 (40.1%) patients were on a basal–bolus regimen (glargine and regular insulin), and 19 (11.7%) patients were on only short-acting insulin. The total requirement of insulin was 0.38 units/kg/day, and out of the total requirement of insulin, 78% were short-acting insulin (regular human insulin). Eighty-seven patients (53.7%) (<40 years) with poorly controlled (HbA1c >9%) on insulin with a mean duration of diabetes (2.66 ± 0.15 years) were added on pioglitazone (Maximum Dose 30 mg) or metformin (Maximum Dose 2500 mg). In the pioglitazone group, there was a significant decrease in the HbA1c (11.01 ± 2.81 vs 9.46 ± 2.31, P < 0.001) along with a significant decrease in the insulin requirement (31.2 ± 11.39 vs 28.1 ± 11.74 units, P < 0.001) from baseline [Table 2]. Table 2Effect of pioglitazone on FCPD cohortFCPD patients on pioglitazonePre- pioglitazonePost-pioglitazoneHbA1C11.01±2.81%9.46±2.31% (P<0.001)Insulin requirements31.2±11.39 units28.1±11.74 Units (P<0.001)Paired t-test was used, with P<0.05 considered significant Effect of pioglitazone on FCPD cohort Paired t-test was used, with P<0.05 considered significant Microvascular complications were identified in 36 patients (22.2%). Distal symmetric polyneuropathy was the most common complication observed in 30 patients (18.5%), followed by diabetic retinopathy in 10 patients (6.1%) and diabetic nephropathy in 2 patients (1.2%). Only one patient developed pancreatic head adenocarcinoma without metastasis who underwent Whipple’s surgery and chemotherapy. DISCUSSION We report the demographic profile of patients with FCPD from the previously unreported region of India. This study included 162 patients with FCPD. Only 21.6% of patients reported features suggestive of malabsorption and FCPD was correctly identified at initial presentation in only 10.6% of cases. The mean delay between the onset of diabetes and the diagnosis of FCPD was 2.83 ± 1.8 years. Progressive weight loss and frequent severe hypoglycaemia despite insulin therapy were notable clinical features. The mean insulin requirement was 0.38 units/kg/day, predominantly short-acting insulin. Among 55 patients treated with pioglitazone, significant reductions in HbA1c and insulin dose were observed over follow-up (P < 0.001 for both). The mean age of presentation in our study was higher compared to the previous literature from India. In one of the largest Indian series from Chennai by Mohan et al., the mean age at diagnosis of FCPD was 24.3 years, with the onset of symptoms typically a few years earlier.[14] In a Bangladesh cohort study by Chowdhury et al. mean age at diagnosis was 23 years, and 75% were diagnosed before age 30.[15] Chandak et al.’s genetic study (SPINK1 mutations) found a mean age at onset of diabetes was 20.5 ± 6.3 years, aligning with earlier epidemiological findings.[6] The change in the age spectrum in our cohort could be partly explained by the fact that 45 patients (compared to the classic young cohort) had an age of presentation of more than 50 years. This shows changes in the spectrum of disease. Remaining demographic features like BMI and other anthropometric parameters were comparable to published literature. Chronic diarrhoea was seen in only 21.6% of the patients, which is considerably lower than that reported in earlier studies. Mohan et al. reported steatorrhea in approximately 85% of patients with FCPD, consistent with significant exocrine pancreatic dysfunction. Diarrhoea was present in a significant proportion often described as bulky, foul-smelling stools.[16] Ramakrishna et al. reported that malabsorption symptoms, including diarrhoea were present in up to 70% of FCPD patients with associated fat-soluble vitamin deficiencies.[17] Frequent severe hypoglycaemia (76.8%) and progressive weight loss despite insulin therapy (76.5%) were common in our cohort and appeared more pronounced than in previously reported series, underscoring a distinctive clinical phenotype. In our cohort, the mean daily insulin requirement was 0.38 units/kg, which was substantially lower than that typically reported in type 1 diabetes (approximately 1 unit/kg/day). Similar to observations in earlier FCPD series[5678] insulin therapy was predominantly short-acting and 19 patients (11.7%) achieved glycaemic control with short-acting insulin alone. These findings are consistent with previously published studies and likely reflect partial preservation of endogenous β-cell function in FCPD. In a subset of patients who received pioglitazone, there was a significant decrease in HbA1c and insulin requirement. This could be attributed to the underlying insulin resistance in these patients. Mohan et al.[16] studied insulin resistance in 12 patients with FCPD by using oral glucose tolerance test, and compared them with 10 normoglycaemic subjects. They found equal glucose disposal rate (a marker of insulin sensitivity) between FCPD and T2DM.[16] This suggests FCPD patients have insulin resistance comparable to that of T2DM. Singla et al.[7] also evaluated the insulin resistance in FCPD patients by using the homeostasis model assessment of insulin resistance (HOMA-IR) and body fat percentage. In 37 patients of FCPD, they found insulin resistance in 77.42% of patients, and it was well correlated with body fat percentage. This study further validated a pathogenetic role for insulin resistance in FCPD. The pioglitazone cohort was found to be effective in contrast to metformin, which showed no improvement in glycemic control. In regard to the observations of Shivaprasad et al.,[6] this could be partly explained by the fact that in FCPD, hepatic insulin resistance is one of the prime contributors to glycemic deterioration. The observed benefit with pioglitazone may relate to improvement in hepatic insulin resistance and is more effective than metformin in non-alcoholic steatohepatitis, with reductions in hepatic steatosis, inflammation, and ballooning, and possible improvement in fibrosis.[18] Unlike metformin, pioglitazone has demonstrated consistent histological benefits in non-alcoholic steatohepatitis, which may explain its greater efficacy in insulin-resistant states such as FCPD.[181920] We have reported the overall prevalence of microvascular complications as 22.2%, and peripheral neuropathy (18.5%) was the most common, followed by retinopathy (6.1%) and nephropathy (1.2%). In our cohort, the prevalence of microvascular complications was lower than that reported in several Indian series of FCPD. This discrepancy could be partly explained by the retrospective nature of the study, as well as by heterogeneity in screening practices,[21] duration of diabetes, and referral patterns across centres, which could influence complication detection when compared with previously published cohorts.[678] The limitations of this study include its retrospective design and the lack of evaluation of insulin resistance and residual β-cell function. Follow-up duration for treatment response was short, and long-term safety outcomes could not be assessed. CONCLUSION FCPD should be suspected in patients with recurrent hypoglycaemic episodes on insulin therapy accompanied by progressive weight loss. Glycemic management was predominantly achieved with short-acting insulin preparations, with minimal requirement for basal insulin. In selected younger patients (<40 years) with evidence of residual β-cell function, adjunctive pioglitazone therapy may improve glycemic control by reducing underlying insulin resistance. However, these observations require confirmation in adequately powered prospective validation studies. Author contribution All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Don David and Manjunath Goroshi. The first draft of the manuscript was written by Don David and contributed by Manjunath Goroshi and Vikrant Ghatnatti, Vanishri Ganakumar commented on previous versions of the manuscript. All authors read and approved the final manuscript. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence There was no use of artificial intelligence in the preparation of manuscript. Data availability statement The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.